Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
ReplyLetter

Dr. Fleischmann replies

ROY FLEISCHMANN
The Journal of Rheumatology December 2019, 46 (12) 1642; DOI: https://doi.org/10.3899/jrheum.190603
ROY FLEISCHMANN
Clinical Professor of Medicine, Metroplex Clinical Research Center, Dallas, Texas, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for ROY FLEISCHMANN
  • For correspondence: rfleischmann@arthdocs.com
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

I am honored that Dr. Calabrese read my editorial, “Value of the multibiomarker disease activity score to predict remission in RA: what does the evidence show?” with interest1. As always, I have great respect for his contributions to rheumatology, particularly in his area of specific expertise; I have also found that he is generally a critical and logical thinker who has advanced our knowledge greatly over the years.

I fully agree with his statement, “this biomarker, along with ALL biomarkers, will fail to answer these questions [the ones I posed in the editorial] in a binary fashion2.” That is the point of the editorial — there is no “biomarker” that answers these questions in a binary fashion or close to it. In particular, the MBDA has not been shown in a well-designed, prospective, properly controlled clinical study, in relevant disease populations, to answer the question of how well it does define, in a specific patient, the disease activity, clinical state, function, or radiographic progression, and how well the MBDA predicts response to the patient’s therapy clinically, functionally, or radiographically. The manufacturer (and its supporters, both academic and practitioners) has relied on posthoc analyses of registries and studies in which these questions were neither prospectively designed nor asked, and using unusual statistical methods at times to make their arguments3. Occasionally the “evidence” is anecdotal, such as the examples that Dr. Calabrese uses of the effectiveness of the MBDA2. Despite these very significant shortcomings, the manufacturer and its supporters strongly suggest (if not proclaim) that the MBDA is an effective tool to help diagnose and manage rheumatoid arthritis (RA) and that it has great value as a prospective biomarker for radiographic progression, such as in the article referenced by Dr. Calabrese4. Many of these articles have alluded to the statistically significant correlation of the results of the MBDA with whatever metric is being discussed; frequently what is not mentioned is that the statistically significant correlations are poor.

Yet, in the only prospective, well-designed, properly controlled trial in which these questions could be answered, the MBDA was found to be significantly lacking clinically, functionally, and radiographically5. In a prespecified analysis from the AMPLE study, there was no statistically significant highly correlated association between the MBDA score and disease activity defined by the Clinical Disease Activity Index, the Simplified Clinical Disease Activity Index, the 28-joint Disease Activity Score using C-reactive protein, or Routine Assessment of Patient Index Data 3 in either the abatacept or adalimumab treatment arms, nor was there a positive correlation between disease activity assessed by the MBDA and radiographic progression5. It was also pointed out in the editorial questioned by Dr. Calabrese that posthoc analyses from the DRESS and RETRO studies were consistent with the inability of the MBDA to predict flares with medication tapering1.

Dr. Calabrese is quite correct, of course, that frequently we as rheumatologists cannot be sure what to do in a specific clinical situation in which complaints and physical findings are discordant2. Laboratory tests evaluating inflammation and imaging such as ultrasound may be beneficial, but not always. The question is whether it is best to rely on “expert opinion” and anecdotal evidence to decide, as Dr. Calabrese suggests, or on evidence from well-designed prospective, peer-reviewed published studies that have critically evaluated the situation. Dr. Calabrese’s opinion, based on his experience and anecdotal evidence, is that the MBDA is very useful in the treatment of RA2. My opinion, based on the most current peer-reviewed evidence in multiple studies, is that it is not, and it is certainly not worth the expense to the patient or the insurer.

REFERENCES

  1. 1.↵
    1. Fleischmann R
    . Value of the multibiomarker of disease activity score to predict remission in RA: what does the evidence show? J Rheumatol 2019;46:443–6.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Calabrese LH
    . MBDA: a valuable tool for medical decision making. J Rheumatol 2019;46:1642.
    OpenUrlFREE Full Text
  3. 3.↵
    1. Curtis JR,
    2. Wright GC,
    3. Strand V,
    4. Davis CS,
    5. Hitraya E,
    6. Sasso EH
    . Reanalysis of the multi-biomarker disease activity score for assessing disease activity in the abatacept versus adalimumab comparison in biologic-naive rheumatoid arthritis subjects with background methotrexate study: comment on the article by Fleischmann, et al. Arthritis Rheumatol 2017;69:863–5.
    OpenUrl
  4. 4.↵
    1. Curtis JR,
    2. Brahe CH,
    3. Østergaard M,
    4. Lund H,
    5. Hetland M,
    6. Hambardzumyan K,
    7. Saevarsdottir S,
    8. et al.
    Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. Curr Med Res Opin 2019;14:1–11.
    OpenUrl
  5. 5.↵
    1. Fleischmann R,
    2. Connolly SE,
    3. Maldonado MA,
    4. Schiff M
    . Brief report: estimating disease activity using multi-biomarker disease activity scores in rheumatoid arthritis patients treated with abatacept or adalimumab. Arthritis Rheumatol 2016;68:2083–9.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 12
1 Dec 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dr. Fleischmann replies
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dr. Fleischmann replies
ROY FLEISCHMANN
The Journal of Rheumatology Dec 2019, 46 (12) 1642; DOI: 10.3899/jrheum.190603

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Dr. Fleischmann replies
ROY FLEISCHMANN
The Journal of Rheumatology Dec 2019, 46 (12) 1642; DOI: 10.3899/jrheum.190603
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • To the Editor:
    • REFERENCES
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Some Key Issues Relating to the Reporting and Interpretation of Time-to-event Data
  • Dr. Griffiths et al reply
  • Baricitinib for Refractory Eosinophilic Fasciitis: Myth or Reality?
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire